Immunotherapy Clinical Trials in Shanghai
12 recruitingShanghai, China
Showing 1–12 of 12 trials
Recruiting
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
Robotic SurgeryStage IIB-III NSCLCNeoadjuvant Chemoimmunotherapy+1 more
Shanghai Chest Hospital100 enrolled10 locationsNCT07541521
Recruiting
Phase 3
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Esophageal CarcinomaRadiotherapyImmunotherapy
Fudan University452 enrolled1 locationNCT06964568
Recruiting
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
Stage IIB-III NSCLCNeoadjuvant ChemoimmunotherapyRobotic Pulmonary Resection
Shanghai Chest Hospital200 enrolled10 locationsNCT07528066
Recruiting
Early Phase 1
A Study of TIL in Advanced Solid Tumors (DFGD)
Advanced Solid TumorTreatment Side EffectsEffects of Immunotherapy+1 more
Shanghai Juncell Therapeutics30 enrolled1 locationNCT06488950
Recruiting
Early Phase 1
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
Breast CancerAdvanced Breast CancerTreatment Side Effects+1 more
Shanghai Juncell Therapeutics50 enrolled1 locationNCT05142475
Recruiting
Early Phase 1
A Study of GC101 TIL in Advanced Melanoma (10hospital)
Advanced MelanomaTreatment Side EffectsEffects of Immunotherapy+1 more
Shanghai Juncell Therapeutics50 enrolled1 locationNCT05098184
Recruiting
Phase 2
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
Rectal CancerRectal AdenocarcinomaTargeted Therapy+6 more
Ruijin Hospital104 enrolled1 locationNCT07198165
Recruiting
Phase 2
Perioperative Immunotherapy for Resectable Limited-Stage SCLC
Perioperative ImmunotherapyLimited Stage Lung Small Cell CarcinomaResectable Small Cell Lung Cancer
Fudan University37 enrolled1 locationNCT07109401
Recruiting
Phase 2
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
Gastric CancerImmunotherapyToripalimab+1 more
Shanghai Changzheng Hospital24 enrolled1 locationNCT04278222
Recruiting
Phase 1Phase 2
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
Locally Advanced Cervical CarcinomaImmunotherapyConcurrent Chemoradiotherapy
RenJi Hospital20 enrolled1 locationNCT06391190
Recruiting
the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer
Locally Advanced Cervical CarcinomaImmunotherapyConcurrent Chemoradiotherapy
RenJi Hospital20 enrolled1 locationNCT06378840
Recruiting
Phase 4
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
ImmunotherapyMDR-TB
Shanghai Pulmonary Hospital, Shanghai, China30 enrolled2 locationsNCT05493267